FDA grants fast-track status to Rebiotix's stool transplant

06/25/2013 | Minneapolis/St. Paul Business Journal

Rebiotix has received fast-track designation from the FDA for its fecal transplant, which could speed up marketing approval for the product. The Roseville, Minn.-based biotech startup intends to use the product for patients with Clostridium difficile, a type of hospital-acquired bacterial infection.

View Full Article in:

Minneapolis/St. Paul Business Journal

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR